"I wanted as much to initiate a cancer immune response as I wanted to initiate one against infection."
This is what Dr. Steinman would love to see. Now NWBO has made his dream a reality. Dr. Liau said that in combo trial the immune response from patients was so drastic that patients had to go through surgery.
They tried to get approved based on a P2 that failed the primary endpoint of PFS but was stat sig on the secondary endpoint of OS. The FDA said that is no good and they needed a real P3 trial that properly defined the prospective OS endpoint in advance.
I think there have been a few changes in FDA's thinking since 2009.